Oruka Therapeutics (ORKA) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 221.4% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with +145.3% for ORKA. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $5.44 billion), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | SMMT |
|---|---|---|
| Share price | $82.11 | $17.59 |
| Market cap | $5.44B | $14.03B |
| 1-day change | +6.25% | +2.45% |
| YTD return | +170.90% | +0.57% |
| 1-year return | +221.37% | -22.34% |
| 5-year return | +145.25% | +241.55% |
| EPS (TTM) | $-2.04 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-105.43M | $-1.08B |
| 52-week high | $115.52 | $29.23 |
| 52-week low | $24.46 | $12.07 |
| Distance from 52-week high | -28.92% | -39.82% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +88.77% | +69.30% |
| Average volume | 907.59K | 5.87M |
| Shares outstanding | 66.21M | 797.75M |
| Employees | 68 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Summit Therapeutics is about 2.6 times larger than Oruka Therapeutics by market value ($14.03B vs $5.44B).
- ORKA has outperformed SMMT by 243.7 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
ORKA vs SMMT FAQ
Which is bigger, Oruka Therapeutics or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $5.44B for Oruka Therapeutics (ORKA).
Which stock has performed better over the past year, ORKA or SMMT?
ORKA returned +221.37% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Summit Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Oruka Therapeutics and Biotechnology: Pharmaceutical Preparations for Summit Therapeutics.